Pain Management News and Research

RSS

China SFDA approves clinical trial of China Aoxing's abuse resistant opioid drug

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that its Clinical Trial Application ("CTA") for Tilidine/Naloxone Capsules, an opioid drug with abuse resistance property, was officially approved by the China State Food and Drug Administration ("SFDA").

17 Sep 2009

Mayo Clinic Health Letter discusses kidney stone treatment options

Ordinary, loud snoring doesn't seem to be harmful, according to the September issue of Mayo Clinic Health Letter. But snorers still may want to seek treatment to stop snoring, reduce embarrassment and improve sleep for themselves and their bed partner.

17 Sep 2009

Melbourne's national approach for managing chronic pain

An unprecedented gathering of some of Australia's leading authorities in pain medicine, together with consumer groups representing chronic pain sufferers, will meet in Melbourne today to work towards a national, coordinated approach to managing chronic pain.

17 Sep 2009

Somatic Systems launches its second Clinical Somatics Professional Training Program

Somatic Systems, Inc. is pleased to announce the launch of a second Clinical Somatics Professional Training Program this year. The program will begin December 5, and feature a convenient, innovative modular format to accommodate a variety of professional schedules.

16 Sep 2009

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product.

15 Sep 2009

Somatic Systems accelerates efforts on projects to provide pain care services to the US Military

Somatic Systems, Inc. (PINKSHEETS: SMAS) stated that they have accelerated their efforts on their projects to provide pain care services to the US Military and establish Military health insurance coverage for Somatic Systems' powerful Clinical Somatics pain treatment method.

15 Sep 2009

Dominion develops and validates clinical quantitative assays for tapentadol

Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

15 Sep 2009

Smith & Nephew's Endoscopy Division announces its inaugural fellowship meeting

Smith & Nephew's Endoscopy Division announced the kick-off of its inaugural fellowship meeting, The Wider Scope of Arthroscopy, at its global headquarters in Andover, Mass., starting today, Sept. 14 through Sept. 15. The event is also being supported by DJO, a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management.

14 Sep 2009

PPJ Enterprise focuses on business development of the medical billing firm PBS

PPJ Enterprise (PPJ) (PINKSHEETS: PPJE), a leader in proprietary automated healthcare multi-specialty provider reimbursement cycle technology and EHR development/information management digital system software for health care providers. PPJ Enterprises has focused all of its resources currently on the strategic business development of the medical billing firm PBS.

11 Sep 2009

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

ORT remains underutilized in U.S. prison systems

Almost a quarter of a million individuals addicted to heroin are incarcerated in the United States each year. However, many prison systems across the country still do not offer medical treatment for heroin and opiate addiction, despite the demonstrated social, medical and economic benefits of opiate replacement therapy (ORT).

9 Sep 2009

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

The first results of the first European survey of cancer patients' experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

9 Sep 2009

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, has announced the launch of an advocacy campaign to fight reimbursement cuts to point-of-care (POC) urine drug screen devices.

9 Sep 2009

SCA collaborates with Surgical Hospital to expand its services

Surgical Hospital of Oklahoma, located in Oklahoma City, today announced that it has partnered with Surgical Care Affiliates (SCA), one of the country's largest providers of specialty surgical services.

4 Sep 2009

China Aoxing submits an NDA to the China SFDA for its Codeine Phosphate

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, today announced that it has submitted a new drug application (NDA) to the China State Food and Drug Administration (SFDA) for its Codeine Phosphate, a compound oral solution for the treatment of acute moderate to severe cough.

3 Sep 2009

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company is pleased to announce that the company has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.

31 Aug 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation (ABNR) involves a safe, medically-assisted withdrawal from Benzodiazepines in a hospital setting. This advanced approach to Benzodiazepine withdrawal offers patients another alternative to traditional benzodiazepine detoxification, which even when done gradually, can be extremely dangerous and even life threatening.

29 Aug 2009

DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY

DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT's manufacturing cost plus a specified percentage mark-up, two key excipients used in the manufacture of REMOXY.

27 Aug 2009

Pain Management News and Research

China SFDA approves clinical trial of China Aoxing's abuse resistant opioid drug

Mayo Clinic Health Letter discusses kidney stone treatment options

Melbourne's national approach for managing chronic pain

Somatic Systems launches its second Clinical Somatics Professional Training Program

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

Somatic Systems accelerates efforts on projects to provide pain care services to the US Military

Dominion develops and validates clinical quantitative assays for tapentadol

Smith & Nephew's Endoscopy Division announces its inaugural fellowship meeting

PPJ Enterprise focuses on business development of the medical billing firm PBS

Campaign to educate customers on chronic pain management

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

ORT remains underutilized in U.S. prison systems

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

SCA collaborates with Surgical Hospital to expand its services

China Aoxing submits an NDA to the China SFDA for its Codeine Phosphate

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Inhibitor Education Summits to address pertinent topics regarding hemophilia

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News